Effects of topoisomerase I inhibition on the expression of topoisomerase IIα measured with fluorescence image cytometry

Cytometry

Volumn 25, Issue 3, 1996, Pages 205-210

  Nicklee, Trudey ^a   Crump, Michael ^b   Hedley, David W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Acute myeloid leukemia; Drug resistance; Topotecan

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; ISOMERASE INHIBITOR; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ARTICLE; CELL CYCLE; CYTOMETRY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODY SPECIFICITY; CAMPTOTHECIN; CELL CYCLE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; FLUORESCENCE; HUMANS; IMAGE CYTOMETRY; LEUKEMIA, MYELOID; RABBITS; TOPOTECAN; TUMOR CELLS, CULTURED;

ORYCTOLAGUS CUNICULUS; TRIXIS;

EID: 0029985042     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19961101)25:3<205::AID-CYTO1>3.0.CO;2-E     Document Type: Article

References (12)

1. Anzai H, Frost P, Abbruzzesse JL: Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc AACR 33: 431, 1992 (Abstract).
2. Beidler DR, Cheng Y-C: Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmcol 47:907-914, 1995.
3. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaekcle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W, Yarosh D: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783-788, 1996.
4. 6-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol 37:547-555, 1996
5. Brown GA, McPherson JP, Gu L, Hedley DW, Toso T, Deuchars KL, Freedman MH, Goldenberg GJ: Relationship of DNA topoisomerase IIα and β expression in cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55:78-82, 1995.
6. Chen M, Beck WT: Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 55:1509-1516, 1995.
7. Pantazis P: Preclinical studies of water-insoluble camptothecin congeners: Cytotoxicity, development of resistance, and combination treatments. Clin Cancer Res 1:1235-1244, 1995.
8. Pommier Y, Kohlhagen G, Kohn F, Leteutre F, Wani MC, Wall ME: Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92: 8861-8865, 1995 (Abstract).
9. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y-C, Grochow LB, Kaufmann SH: Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994.
10. Smith PJ, Soues S: Multilevel therapeutic targeting by topoisomerase inhibitors. [Review]. Br J Cancer Suppl 23:S47-S51, 1994.
11. Thomas M, Nicklee T, Hedley DW: Differential effects of depleting agents on cytoplasmic and nuclear non-protein sulphydryls: A fluorescence image cytometry study. Br J Cancer 72:45-50, 1995.
12. Webb CD, Latham MD, Lock RB, Sullivan DM: Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543-6549, 1991.